Dexrazoxane Treatments Limits Subclinical Cardiac Dysfunction in Childhood Acute Lymphoblastic Leukemia Survivors Exposed to Doxorubicin Treatments
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002538
Abstract: Introduction: Doxorubicin leads to dose dependent cardiotoxicity in childhood acute lymphoblastic leukemia (ALL) survivors. We investigated survivors’ heart health using echocardiography and evaluated doxorubicin and dexrazoxane treatments on cardiac function. Methods: A total of 196… read more here.
Keywords: oncology; childhood acute; childhood; dexrazoxane ... See more keywords